Table 2.

Fold changes in GH concentrations following acute resistance exercise

ComparisonNIDDK Polyclonal ImmunoassayNichols Monoclonal ImmunoassayRat Tibial Line In Vivo Bioassay
T1 vs. T2T3 vs. T4T1 vs. T2T3 vs. T4T1 vs. T2T3 vs. T4
FractionUFABCUFABCUFABCUFABCUFABCUFABC
TB strength1.01.31.52.71.20.82.11.43.01.61.51.21.71.01.91.90.40.0−0.30.5−0.10.90.00.2
TB hypertrophy1.11.93.02.02.10.81.82.11.82.53.02.17.02.08.06.60.4−0.20.5−0.3−0.10.20.60.1
UB strength1.70.72.11.11.70.13.30.92.72.01.90.83.70.40.92.40.0−0.1−0.20.20.30.00.20.2
UB hypertrophy1.20.81.01.51.00.91.42.42.12.72.11.43.32.32.12.2−0.10.20.1−0.10.20.10.00.7
Control1.50.12.13.01.10.11.92.62.30.21.10.91.90.31.11.00.00.10.10.20.10.10.10.1
  • Changes are shown for each testing session (pretraining and posttraining), each assay detection system, and each training program. GH, growth hormone; T1, week 0, preexercise blood draw; T2, week 0, postexercise blood draw; T3, week 24, preexercise blood draw; T4, week 24, postexercise blood draw; NIDDK, National Institute of Diabetes and Digestive and Kidney Diseases; UF, unfractionated; A, fractionated (>60 kDa); B, fractionated (30–60 kDa); C, fractionated (<30 kDa); UB, upper body; TB, total body. Values in regular font indicate nonsignificant changes from pre- to postexercise. Bold values indicate significant (P < 0.05) increases from pre- to postexercise. Italicized values indicate significant (P < 0.05) decreases from pre- to postexercise.